The MedicalXpress report highlights a plasma model using two tau isoforms that matched PET staging accuracy in over 1,000 participants spanning cognitively normal, mild cognitive impairment, Alzheimer's dementia, and other neurodegenerative cases. This observational cohort study, published in JAMA Neurology, demonstrates strong concordance without detailing randomization or blinding protocols typical of RCTs, leaving room for selection bias. Sample size exceeds most prior tau blood-biomarker validations, yet the authors and external reviewer Dr. D'Amico both flag the need for larger, diverse replication. Unlike drug-centric coverage, this development could democratize biological staging beyond specialized centers, addressing access gaps that currently limit anti-amyloid therapies such as lecanemab to PET- or CSF-confirmed patients. Related work in Nature Medicine (2024) on plasma p-tau217 showed similar staging utility in 1,400 Swedish and U.S. cohorts but lacked direct comparison to dual-isoform ratios; a 2023 Alzheimer's & Dementia multi-site study further linked rising plasma tau ratios to longitudinal cognitive decline independent of amyloid load. Missed in initial reporting is the test's potential to shift primary-care screening paradigms, enabling risk stratification years before symptoms and informing preventive trials at scale. Equity implications remain under-examined: lower-cost venipuncture could reduce racial disparities in biomarker access documented in prior observational registries. Conflicts of interest are unreported in the source summary, underscoring the importance of forthcoming independent validations.